Behavioural and pharmacological examinations in a transgenic mouse model of early-onset torsion dystonia

Pharmacology Biochemistry and Behavior

Volumn 97, Issue 4, 2011, Pages 647-655

  Lange, Nikola ^a   Hamann, Melanie ^a   Shashidharan, Pullani ^b   Richter, Angelika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Basal ganglia; Dopamine; DYT1; Movement disorder

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 1 AMINOMETHYL 5,6 DIHYDROXY 3 PHENYLISOCHROMAN; CARBIDOPA; LEVODOPA; QUINPIROLE; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; GENOTYPE; LOCOMOTION; MOTOR ACTIVITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; STEREOTYPY; TORSION DYSTONIA; TRANSGENIC MOUSE;

AMPHETAMINES; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CARBIDOPA; CHROMANS; DISEASE MODELS, ANIMAL; DYSTONIA; LEVODOPA; LOCOMOTION; MICE; MICE, TRANSGENIC; QUINPIROLE; RACLOPRIDE;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 78650037405     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.11.005     Document Type: Article

References (46)

1. W. Adriani, and G. Laviola Spontaneous novelty seeking and amphetamine-induced conditioning and sensitization in adult mice: evidence of dissociation as a function of age at weaning Neuropsychopharmacology 27 2002 225 236
2. K. Asanuma, Y. Ma, J. Okulski, V. Dhawan, T. Chaly, and M. Carbon Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation Neurology 64 2005 347 349
3. W. Auerbach, M.S. Hurlbert, P. Hilditch-Maguire, Y.Z. Wadghiri, V.C. Wheeler, and S.I. Cohen The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin Hum Mol Genet 10 2001 2515 2523
4. S.J. Augood, Z. Hollingsworth, D.S. Albers, L. Yang, J.C. Leung, and B. Muller Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study Neurology 59 2002 445 448
5. S.J. Augood, C.E. Keller-McGandy, A. Siriani, J. Hewett, V. Ramesh, and E. Sapp Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain Brain Res 986 2003 12 21
6. S.J. Augood, Z. Hollingsworth, D.S. Albers, L. Yang, J. Leung, and X.O. Breakefield Dopamine transmission in DYT1 dystonia Adv Neurol 94 2004 53 60
7. A.L. Baird, A. Meldrum, and S.B. Dunnett The staircase test of skilled reaching in mice Brain Res Bull 54 2001 243 250
8. A. Balcioglu, M.O. Kim, N. Sharma, J.H. Cha, X.O. Breakefield, and D.G. Standaert Dopamine release is impaired in a mouse model of DYT1 dystonia J Neurochem 102 2007 783 788
9. Bandmann O., and Müler U. Rieß O. Schöls L. Dystonie Neurogenetik 2 2002 Köln Kohlhammer Stuttgart; Berlin 338 345
10. X.O. Breakefield, A.J. Blood, Y. Li, M. Hallett, P.I. Hanson, and D.G. Standaert The pathophysiological basis of dystonias Nat Rev Neurosci 9 2008 222 234
11. Bressman S. Genetics of dystonia J Neural Transm Suppl 2006 489 495
12. M.S. Buckwalter, C.M. Testa, J.L. Noebels, and S.A. Camper Genetic mapping and evaluation of candidate genes for spasmodic, a neurological mouse mutation with abnormal startle response Genomics 17 1993 279 286
13. S. Chiken, P. Shashidharan, and A. Nambu Cortically evoked long-lasting inhibition of pallidal neurons in a transgenic mouse model of dystonia J Neurosci 28 2008 13967 13977
14. J.N. Crawley What's Wrong with my Mouse 2000 Wiley-Liss New York
15. S.A. Daly, and J.L. Waddington Two directions of dopamine D1/D2 receptor interaction in studies of behavioural regulation: a finding generic to four new, selective dopamine D1 receptor antagonists Eur J Pharmacol 213 1992 251 258
16. M.T. Dang, F. Yokoi, K.S. McNaught, T.A. Jengelley, T. Jackson, and J. Li Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia Exp Neurol 196 2005 452 463
17. M.T. Dang, F. Yokoi, M.A. Pence, and Y. Li Motor deficits and hyperactivity in Dyt1 knockdown mice Neurosci Res 56 2006 470 474
18. N.A. Darmani Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the d-fenfluramine-induced head-twitch response in mice Pharmacol Biochem Behav 60 1998 83 90
19. A.M. Deveney, and J.L. Waddington Psychopharmacological distinction between novel full-efficacy "D1-like" dopamine receptor agonists Pharmacol Biochem Behav 58 1997 551 558
20. C.E. Gross, P. Ravenscroft, S. Dovero, M. Jaber, B. Bioulac, and E. Bezard Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice J. Neurochem. 84 2003 1246 1255
21. S. Fahn, S.B. Bressman, and C.D. Marsden Classification of dystonia Adv Neurol 78 1998 1 10
22. P.O. Fernagut, E. Diguet, B. Labattu, and F. Tison A simple method to measure stride length as an index of nigrostriatal dysfunction in mice J Neurosci Meth 113 2002 123 130
23. K. Grundmann, B. Reischmann, G. Vanhoutte, J. Hubener, P. Teismann, and T.K. Hauser Overexpression of human wildtype torsinA and human DeltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities Neurobiol Dis 27 2007 190 206
24. M. Hamann, and A. Richter Striatal increase of extracellular dopamine levels during dystonic episodes in a genetic model of paroxysmal dyskinesia Neurobiol Dis 16 2004 78 84
25. M. Hamann, M.H. Meisler, and A. Richter Motor disturbances in mice with deficiency of the sodium channel gene Scn8a show features of human dystonia Exp Neurol 184 2003 830 838
26. G.A. Heiman, R. Ottman, R.J. Saunders-Pullman, L.J. Ozelius, N.J. Risch, and S.B. Bressman Increased risk for recurrent major depression in DYT1 dystonia mutation carriers Neurology 63 2004 631 637
27. M.Y. Heng, P.J. Detloff, and R.L. Albin Rodent genetic models of Huntington disease Neurobiol Dis 32 2008 1 9
28. J.C. Horvitz, G. Williams, and R. Joy Time-dependent actions of D2 family agonist quinpirole on spontaneous behavior in the rat: dissociation between sniffing and locomotion Psychopharmacology (Berl) 154 2001 350 355
29. J. Jankovic Treatment of dystonia Lancet Neurol 5 2006 864 872
30. R. Lalonde Motor abnormalities in staggerer mutant mice Exp Brain Res 68 1987 417 420 (Pubitemid 18067575)
31. R. Lalonde Motor abnormalities in weaver mutant mice Exp Brain Res 65 1987 479 481 (Pubitemid 17002311)
32. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur J Neurosci 15 2002 120 132
33. E.I. Miklyaeva, W. Dong, A. Bureau, R. Fattahie, Y. Xu, and M. Su Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system Brain Res 1001 2004 37 50
34. T. Ogura, and A.J. Wilkinson AAA+ superfamily ATPases: common structure-diverse function Genes Cells 6 2001 575 597
35. L.J. Ozelius, J.W. Hewett, C.E. Page, S.B. Bressman, P.L. Kramer, and C. Shalish The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein Nat Genet 17 1997 40 48
36. A. Parra, M.C. Arenas, S. Monleon, C. Vinader-Caerols, and V.M. Simon Sex differences in the effects of neuroleptics on escape-avoidance behavior in mice: a review Pharmacol Biochem Behav 64 1999 813 820
37. A. Pisani, G. Martella, A. Tscherter, P. Bonsi, N. Sharma, and G. Bernardi Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia Neurobiol Dis 24 2006 318 325
38. L.P. Quinn, T.O. Stean, H. Chapman, M. Brown, M. Vidgeon-Hart, and N. Upton Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration J Neurosci Meth 156 2006 218 227
39. A. Richter, and W. Löscher Animal models of dystonia Funct Neurol 15 2000 259 267
40. J.O. Rinne, M. Iivanainen, L. Metsahonkala, L. Vainionpaa, L. Paakkonen, and K. Nagren Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors J Neural Transm 111 2004 59 67
41. R.J. Rodgers, and J.C. Cole Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test Eur J Pharmacol 261 1994 321 325
42. K. Rostasy, S.J. Augood, J.W. Hewett, J.C. Leung, H. Sasaki, and L.J. Ozelius TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion Neurobiol Dis 12 2003 11 24
43. Sciamanna G., Bonsi P., Tassone A., Cuomo D., Tscherter A., and Viscomi M.T. Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia Neurobiol Dis 34 2009 133 145
44. N. Sharma, M.G. Baxter, J. Petravicz, D.C. Bragg, A. Schienda, and D.G. Standaert Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation J Neurosci 25 2005 5351 5355
45. P. Shashidharan, D. Sandu, U. Potla, I.A. Armata, R.H. Walker, and K.S. McNaught Transgenic mouse model of early-onset DYT1 dystonia Hum Mol Genet 14 2005 125 133
46. A. Yamamoto, J.J. Lucas, and R. Hen Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 2000 57 66